IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 39.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,208 shares of the company’s stock after buying an additional 2,866 shares during the period. Vontobel Holding Ltd.’s holdings in IDEXX Laboratories were worth $5,666,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IDXX. OFI Invest Asset Management bought a new position in IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Valley National Advisers Inc. lifted its holdings in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares during the last quarter. Altshuler Shaham Ltd bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $26,000. Geo Capital Gestora de Recursos Ltd bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $28,000. Finally, Covestor Ltd lifted its holdings in shares of IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock worth $29,000 after purchasing an additional 28 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold 43,524 shares of company stock worth $24,871,960 in the last three months. 2.11% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IDXX. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. The Goldman Sachs Group raised their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, Barclays raised their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $591.50.

IDEXX Laboratories Stock Down 2.3 %

Shares of IDXX stock opened at $478.24 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $583.39. The stock has a market cap of $39.72 billion, a PE ratio of 47.49, a price-to-earnings-growth ratio of 3.77 and a beta of 1.26. The business’s fifty day moving average is $541.86 and its 200-day moving average is $508.71. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the firm earned $2.05 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.